Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders.
Sci Adv. 2022 Sep 23;8(38):eabn4704. doi: 10.1126/sciadv.abn4704. Epub 2022 Sep 21.
Sci Adv. 2022.
PMID: 36129972
Free PMC article.
Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome.
Collaud F, Bortolussi G, Guianvarc'h L, Aronson SJ, Bordet T, Veron P, Charles S, Vidal P, Sola MS, Rundwasser S, Dufour DG, Lacoste F, Luc C, Wittenberghe LV, Martin S, Le Bec C, Bosma PJ, Muro AF, Ronzitti G, Hebben M, Mingozzi F.
Collaud F, et al. Among authors: guianvarc h l.
Mol Ther Methods Clin Dev. 2018 Dec 31;12:157-174. doi: 10.1016/j.omtm.2018.12.011. eCollection 2019 Mar 15.
Mol Ther Methods Clin Dev. 2018.
PMID: 30705921
Free PMC article.
Item in Clipboard
The EB66® cell line as a valuable cell substrate for MVA-based vaccines production.
Léon A, David AL, Madeline B, Guianvarc'h L, Dureau E, Champion-Arnaud P, Hebben M, Huss T, Chatrenet B, Schwamborn K.
Léon A, et al. Among authors: guianvarc h l.
Vaccine. 2016 Nov 21;34(48):5878-5885. doi: 10.1016/j.vaccine.2016.10.043. Epub 2016 Oct 27.
Vaccine. 2016.
PMID: 27997338
Free article.
Item in Clipboard
Cite
Cite